Reading SGMO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGMO free→Reading SGMO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGMO free→QuarterlyIQ Insights · SGMO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 14, 2026, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Results of Operations and Financial Condition. On March 30, 2026, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Entry into a Material Definitive Agreement. Underwritten Offering On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 35,190,292 shares of the Company’s common stock, par value $0.01 per sh…
Unregistered Sales of Equity Securities. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2, 2026, the employment of Prathyusha Duraibabu, the Company’s principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Sangamo’s Vice President, Finance and Corporate Controller and principal accounting officer, has been appointed to the position of Interim Chief Financial Officer and will serve as the Company’…
is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the C…
Results of Operations and Financial Condition. On November 6, 2025, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended September 30, 2025 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 29, 2025, Sangamo Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set fort…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, Prathyusha Duraibabu resigned from her position as Chief Financial Officer of Sangamo Therapeutics, Inc. (the “Company”), effective October 1, 2025 (the “Transition Date”), and is transitioning to part-time employment with the Company to continue to serve as the Company’s principal financial officer. In connection with Ms.…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2025, Prathyusha Duraibabu, notified Sangamo Therapeutics, Inc. (the “Company”) of her decision to resign from her position as Chief Financial Officer of the Company, effective October 1, 2025 (the “Transition Date”), in order to assume a senior leadership role with a privately-held artificial intelligence company. Ms. Duraibabu’s r…
Results of Operations and Financial Condition. On August 7, 2025, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended June 30, 2025 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Other Events. On June 24, 2025, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Summary of Topline Results from the Registrational Phase 1/2 STAAR Study Evaluating Isaralgagene Civaparvovec • Following a single dose of isaralgagene civoparvovec, a positive mean annua…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 12, 2025, at the annual meeting of stockholders (the “Annual Meeting”) of Sangamo Therapeutics, Inc. (the “Company”), the Company’s stockholders approved the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) to, among other things, (i) increase the aggregate number of shares of common s…
Other Events. On May 12, 2025, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 12,235,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), and pre-funded warrants to purchase 34,398,393 shares of Common…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 30, 2025, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price r…
Results of Operations and Financial Condition. On March 17, 2025, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2024 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Other Events. On February 6, 2025, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) announced updated preliminary clinical data from its Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease, in advance of a presentation at the 21 st Annual WORLD Symposium on February 6, 2025. A summary of the data is below. This announcement included data on the 33 patients treated with isaralgagene civap…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'fair' to 'inexpensive'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.